Freenome, a Bay Area biotech firm focused on early cancer detection through blood-based tests, has announced its plans to go public by merging with Perceptive Capital Solutions Corp in a $330 million SPAC deal. This merger includes a substantial $240 million investment from notable private healthcare investors, including Perceptive Advisors, RA Capital, and ADAR1 Capital Management. The transaction is expected to close in the first half of 2026, allowing Freenome to trade on the Nasdaq under the ticker FRNM.
CEO Aaron Elliott emphasized that this move occurs at a pivotal moment for both the company and the broader field of blood-based cancer screening. Freenome’s technology has achieved clinical validation through its pivotal PREEMPT CRC study and a recent publication in JAMA. With established commercialization partnerships, the company is poised to launch multiple tests in 2026, potentially transforming cancer detection methodologies.
Use the database as your supply chain compass →
